KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Esperion Therapeutics (ESPR) Change in Accured Expenses (2018 - 2025)

Historic Change in Accured Expenses for Esperion Therapeutics (ESPR) over the last 8 years, with Q3 2025 value amounting to $21.2 million.

  • Esperion Therapeutics' Change in Accured Expenses rose 6322.24% to $21.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $24.8 million, marking a year-over-year increase of 2308.07%. This contributed to the annual value of $18.3 million for FY2024, which is 1699.33% down from last year.
  • As of Q3 2025, Esperion Therapeutics' Change in Accured Expenses stood at $21.2 million, which was up 6322.24% from -$1.7 million recorded in Q2 2025.
  • In the past 5 years, Esperion Therapeutics' Change in Accured Expenses ranged from a high of $25.0 million in Q1 2021 and a low of -$21.8 million during Q2 2021
  • Moreover, its 5-year median value for Change in Accured Expenses was $1.2 million (2022), whereas its average is $3.7 million.
  • As far as peak fluctuations go, Esperion Therapeutics' Change in Accured Expenses tumbled by 39493.07% in 2021, and later soared by 69034.06% in 2023.
  • Over the past 5 years, Esperion Therapeutics' Change in Accured Expenses (Quarter) stood at -$789000.0 in 2021, then soared by 255.77% to $1.2 million in 2022, then skyrocketed by 566.8% to $8.2 million in 2023, then dropped by 22.55% to $6.3 million in 2024, then skyrocketed by 233.75% to $21.2 million in 2025.
  • Its Change in Accured Expenses was $21.2 million in Q3 2025, compared to -$1.7 million in Q2 2025 and -$932000.0 in Q1 2025.